CAT-192: Began Phase I testing

Cambridge Antibody Technology Group plc (LSE:CAT), Melbourn, U.K. Product: CAT-192 Business: Biomaterial/Skin/Wound, Dermatology Therapeutic category: Antibody, Cell proliferation Target: TGFbeta Desc...